PART 331—ANTACID PRODUCTS FOR OVER-THE-COUNTER (OTC) HUMAN USE Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371. Source: 39 FR 19874, June 4, 1974, unless otherwise noted. Subpart A—General Provisions § 331.1 Scope. An over-the-counter antacid product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each of the following conditions and each of the general conditions established in § 330.1 of this chapter. Subpart B—Active Ingredients § 331.10 Antacid active ingredients. (a) The active antacid ingredients of the product consist of one or more of the ingredients permitted in § 331.11 within any maximum daily dosage limit established, each ingredient is included at a level that contributes at least 25 percent of the total acid neutralizing capacity of the product, and the finished product contains at least 5 meq of acid neutralizing capacity as measured by the procedure provided in the United States Pharmacopeia 23/National Formulary 18. The method established in § 331.20 shall be used to determine the percent contribution of each antacid active ingredient. (b) This section does not apply to an antacid ingredient specifically added as a corrective to prevent a laxative or constipating effect. [39 FR 19874, June 4, 1974, as amended at 61 FR 4822, Feb. 8, 1996] § 331.11 Listing of specific active ingredients. (a) Aluminum-containing active ingredients: (1) Basic aluminum carbonate gel. (2) Aluminum hydroxide (or as aluminum hydroxide-hexitol stabilized polymer, aluminum hydroxide-magnesium carbonate codried gel, aluminum hydroxide-magnesium trisilicate codried gel, aluminum-hydroxide sucrose powder hydrated). (3) Dihydroxyaluminum aminoacetate and dihydroxyaluminum aminoacetic acid. (4) Aluminum phosphate gel when used as part of an antacid combination product and contributing at least 25 percent of the total acid neutralizing capacity; maximum daily dosage limit is 8 grams. (5) Dihydroxyaluminum sodium carbonate. (b) Bicarbonate-containing active ingredients: Bicarbonate ion; maximum daily dosage limit 200 mEq. for persons up to 60 years old and 100 mEq. for persons 60 years or older. (c) Bismuth-containing active ingredients: (1) Bismuth aluminate. (2) Bismuth carbonate. (3) Bismuth subcarbonate. (4) Bismuth subgallate. (5) Bismuth subnitrate. (d) Calcium-containing active ingredients: Calcium, as carbonate or phosphate; maximum daily dosage limit 160 mEq. calcium (e.g., 8 grams calcium carbonate). (e) Citrate-containing active ingredients: Citrate ion, as citric acid or salt; maximum daily dosage limit 8 grams. (f) Glycine (aminoacetic acid). (g) Magnesium-containing active ingredients: (1) Hydrate magnesium aluminate activated sulfate. (2) Magaldrate. (3) Magnesium aluminosilicates. (4) Magnesium carbonate. (5) Magnesium glycinate. (6) Magnesium hydroxide. (7) Magnesium oxide. (8) Magnesium trisilicate. (h) Milk solids, dried. (i) Phosphate-containing active ingredients: (1) Aluminum phosphate; maximum daily dosage limit 8 grams. (2) Mono or dibasic calcium salt; maximum daily dosage limit 2 grams. (3) Tricalcium phosphate; maximum daily dosage limit 24 grams. (j) Potassium-containing active ingredients: (1) Potassium bicarbonate (or carbonate when used as a component of an effervescent preparation); maximum daily dosage limit 200 mEq. of bicarbonate ion for persons up to 60 years old and 100 mEq. of bicarbonate ion for persons 60 years or older. (2) Sodium potassium tartrate. (k) Sodium-containing active ingredients: (1) Sodium bicarbonate (or carbonate when used as a component of an effervescent preparation); maximum daily dosage limit 200 mEq. of sodium for persons up to 60 years old and 100 mEq. of sodium for persons 60 years or older, and 200 mEq. of bicarbonate ion for persons up to 60 years old and 100 mEq. of bicarbonate ion for persons 60 years or older. That part of the warning required by § 330.1(g), which states, “Keep this and all drugs out of the reach of children” is not required on a product which contains only sodium bicarbonate powder and which is intended primarily for other than drug uses. (2) Sodium potassium tartrate. (l) Silicates: (1) Magnesium aluminosilicates. (2) Magnesium trisilicate. (m) Tartrate-containing active ingredients. Tartaric acid or its salts; maximum daily dosage limit 200 mEq. (15 grams) of tartrate. [39 FR 19874, June 4, 1974, as amended at 51 FR 27763, Aug. 1, 1986; 55 FR 19859, May 11, 1990] § 331.15 Combination with nonantacid active ingredients. (a) An antacid may contain any generally recognized as safe and effective nonantacid laxative ingredient to correct for constipation caused by the antacid. No labeling claim of the laxative effect may be used for such a product. (b) An antacid may contain any generally recognized as safe and effective analgesic ingredient(s), if it is indicated for use solely for the concurrent symptoms involved, e.g., headache and acid indigestion, and is marketed in a form intended for ingestion as a solution. (c) An antacid may contain any generally recognized as safe and effective antiflatulent ingredient if it is indicated for use solely for the concurrent symptoms of gas associated with heartburn, sour stomach or acid indigestion. Subpart C—Testing Procedures § 331.20 Determination of percent contribution of active ingredients. To determine the percent contribution of an antacid active ingredient, place an accurately weighed amount of the antacid active ingredient equal to the amount present in a unit dose of the product into a 250-milliliter (mL) beaker. If wetting is desired, add not more than 5 mL of alcohol (neutralized to an apparent pH of 3.5), and mix to wet the sample thoroughly. Add 70 mL of water, and mix on a magnetic stirrer at 300 ±30 r.p.m. for 1 minute. Analyze the acid neutralizing capacity of the sample according to the procedure provided in the United States Pharmacopeia 23/National Formulary 18 and calculate the percent contribution of the antacid active ingredient in the total product as follows: Percent contribution = (Total mEq. Antacid Active Ingredient × 100)/(Total mEq. Antacid Product). [61 FR 4823, Feb. 8, 1996] § 331.21 Test modifications. The formulation or mode of administration of certain products may require a modification of the United States Pharmacopeia 23/National Formulary 18 acid neutralizing capacity test. Any proposed modification and the data to support it shall be submitted as a petition under the rules established in § 10.30 of this chapter. All information submitted will be subject to the disclosure rules in part 20 of this chapter. [61 FR 4823, Feb. 8, 1996] Subpart D—Labeling § 331.30 Labeling of antacid products. (a) Statement of identity. (b) Indications. (c) Warnings. (1) “Do not take more than (maximum recommended daily dosage, broken down by age groups if appropriate, expressed in units such as tablets or teaspoonfuls) in a 24-hour period, or use the maximum dosage of this product for more than 2 weeks, except under the advice and supervision of a physician.” (2) For products which cause constipation in 5 percent or more of persons who take the maximum recommended dosage: “May cause constipation.” (3) For products which cause laxation in 5 percent or more of persons who take the maximum recommended dosage: “May have laxative effect.” (4) For products containing more than 5 gm per day lactose in a maximum daily dosage: “Do not use this product except under advice and supervision of a physician if you are allergic to milk or milk products.” (d) Drug interaction precaution. 1 1 (e) Directions for use. (f) Exemption from the general accidental overdose warning. (g) [Reserved] (h) The word “doctor” may be substituted for the word “physician” in any of the labeling statements in this section. [39 FR 19874, June 4, 1974, as amended at 47 FR 38484, Aug. 31, 1982; 51 FR 16266, May 1, 1986; 51 FR 27763, Aug. 1, 1986; 52 FR 7830, Mar. 13, 1987; 55 FR 11581, Mar. 29, 1990; 58 FR 45208, Aug. 26, 1993; 59 FR 60556, Nov. 25, 1994; 61 FR 17806, Apr. 22, 1996; 64 FR 13295, Mar. 17, 1999; 69 FR 13734, Mar. 24, 2004] § 331.80 Professional labeling. (a) The labeling of the product provided to health professionals (but not to the general public): (1) Shall contain the neutralizing capacity of the product as calculated using the procedure set forth in United States Pharmacopeia 23/National Formulary 18 expressed in terms of the dosage recommended per minimum time interval or, if the labeling recommends more than one dosage, in terms of the minimum dosage recommended per minimum time interval. (2) May contain an indication for the symptomatic relief of hyperacidity associated with the diagnosis of peptic ulcer, gastritis, peptic esophagitis, gastric hyperacidity, and hiatal hernia. (3) For products containing basic aluminum carbonate gel identified in § 331.11(a)(1)—Indication. (4) For products containing aluminum identified in § 331.11(a) Warnings. (ii) Aluminum forms insoluble complexes with phosphate in the gastrointestinal tract, thus decreasing phosphate absorption. Prolonged use of aluminum-containing antacids by normophosphatemic patients may result in hypophosphatemia if phosphate intake is not adequate. In its more severe forms, hypophosphatemia can lead to anorexia, malaise, muscle weakness, and osteomalacia. (b) Professional labeling for an antacid-antiflatulent combination may contain the information allowed for health professionals for antacids and antiflatulents. [39 FR 19874, June 4, 1974. Redesignated and amended at 55 FR 19859, May 11, 1990]